The Prognostic Value of Serum Biomarkers in Osteosarcoma

Istituto Ortopedico Rizzoli1 site in 1 country600 target enrollmentJuly 12, 2021

ConditionsOsteosarcoma

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Osteosarcoma
Sponsor: Istituto Ortopedico Rizzoli
Enrollment: 600
Locations: 1
Primary Endpoint: Evaluation of 5-year survival
Status: Completed
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Observational retrospective cohort study using laboratory data of blood tests prior to surgical and chemotherapy treatment and other histologic, clinical, and instrumental data related to patient history from digitized medical records and analysis of the same as predictors of outcomes.

Registry

clinicaltrials.gov

Start Date

July 12, 2021

End Date

December 22, 2021

Last Updated

4 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Istituto Ortopedico Rizzoli

Responsible Party

Principal Investigator

Costantino Errani

Principal Investigator

Istituto Ortopedico Rizzoli

Eligibility Criteria

Inclusion Criteria

•Osteosarcoma diagnosed at the Pathological Anatomy of the Rizzoli Orthopaedic Institute in Bologna;
•Minimum 2-year follow-up period;
•Medical records, complete blood work and instrumental examinations, regular follow-up;
•Patients with age ≥ 2 years;

Exclusion Criteria

•Patients with osteosarcoma who have received medical treatment (surgery, radiotherapy or chemotherapy) in other hospitals prior to admission to our Institute